<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03417505</url>
  </required_header>
  <id_info>
    <org_study_id>STM-0686</org_study_id>
    <nct_id>NCT03417505</nct_id>
  </id_info>
  <brief_title>Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye</brief_title>
  <official_title>Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tangible Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nova Southeastern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Illinois College of Optometry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tangible Science</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tangible Hydra-PEG is a novel coating technology designed to improve lens wettability,
      deposit resistance, and tear film breakup time. This is a randomized double masked cross-over
      study to examine contact lens discomfort and dry eye symptoms with Tangible Hydra-PEG treated
      scleral lens wear compared to untreated scleral lens wear in the dry eye patient population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dry eye (DE) is a common complaint of millions of people worldwide with a significant impact
      on quality of life. For decades, this condition has presented a challenge to eye care
      professionals as conventional therapies are often ineffective. Recently, scleral lenses have
      demonstrated to be a promising therapeutic and vision rehabilitative option for dry eye
      sufferers. Nonetheless, despite the benefits of scleral lenses for dry eye patients,
      inadequate wettability of scleral lenses with subsequent diminished comfort and visual
      clarity remains a concern for scleral lens wearers with dry eye.

      Tangible Hydra-PEG (Tangible Science LLC, Menlo Park, CA, USA) is a novel coating technology
      designed to improve lens wettability, deposit resistance, and tear film breakup time,
      ultimately enhancing contact lens comfort. While studies have shown that Tangible Hydra-PEG
      technology can improve contact lens discomfort (CLD) in soft contact lens and gas permeable
      lens wearers, to our knowledge, no clinical research investigation has examined the benefits
      of this new coating on scleral lens wear in dry eye sufferers. As such, the aim of this study
      is to compare the CLD and DE symptoms of dry eye scleral lens wearers between Tangible
      Hydra-PEG treated scleral lens wear and untreated scleral lens wear. CLD and DE signs will
      also be assessed to corroborate our findings.

      This will be the first randomized double masked cross-over study to examine CLD and DE
      symptoms of Tangible Hydra-PEG treated scleral lens wear compared to untreated scleral lens
      wear in the dry eye patient population. Tangible Hydra-PEG treated scleral lenses can
      potentially minimize CLD and DE symptoms, ultimately improving outcomes for patients coping
      with dry eye disease. This study will provide new information about this innovative
      technology and help practitioners envisage rehabilitative options which will best optimize
      the quality of life of this important patient population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Actual">January 4, 2019</completion_date>
  <primary_completion_date type="Actual">January 4, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, double-masked crossover study</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Surface Tear Breakup Time</measure>
    <time_frame>30 days</time_frame>
    <description>Tear breakup time of the ocular surface after wearing lenses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal Fluorescein Staining</measure>
    <time_frame>30 days</time_frame>
    <description>Fluorescein staining followed by assessment using the Oxford grading scale (0-5, where 5 indicates the most staining and therefore the most damage to the ocular surface) of the ocular surface after wearing Hydra-PEG treated lenses compared to control lenses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular Surface Disease Index (OSDI) Questionnaire</measure>
    <time_frame>30 days</time_frame>
    <description>Dry eye questionnaire to assess symptoms after wearing Hydra-PEG treated lenses compared to control lenses. Patients will be scored from 0 (no dry eye disease) to 100 (severe dry eye disease).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)</measure>
    <time_frame>30 days</time_frame>
    <description>Validated dry eye questionnaire to assess symptoms after wearing Hydra-PEG treated lenses compared to control lenses. Scale is from 1 to 37, with higher scores indicating more dry eye symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tear Breakup Time Over the Surface of the Scleral Lens</measure>
    <time_frame>30 days</time_frame>
    <description>Tear breakup time over the surface of the Hydra-PEG treated scleral lens compared to the control lens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lid Wiper Epitheliopathy</measure>
    <time_frame>30 days</time_frame>
    <description>Fluorescein and lissamine staining to assess lid wiper epitheliopathy using a grading scale to see if there is a change in the height and width of the staining of the lid wiper area with Hydra-PEG treated lenses compared to untreated control lenses. The lid wiper area is the portion of the marginal conjunctival epithelium of the upper eyelid that wipes the ocular surface or lens during blinking. Epitheliopathy is scored on a scale from 0 (best patient outcome) to 3 (worst patient outcome, more staining) on the basis of the horizontal and vertical extent of lid margin staining.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contact Lens-related Papillary Conjunctivitis</measure>
    <time_frame>30 days</time_frame>
    <description>Visual inspection for contact lens-related papillary conjunctivitis with scoring by the Efron grading scale for papillary conjunctivitis [0 (normal) to 4 (severe)] to assess changes after wear of Hydra-PEG treated lenses compared to control lenses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Temporal Conjunctival Lissamine Green Staining</measure>
    <time_frame>30 days</time_frame>
    <description>Temporal conjunctival lissamine green staining scored 0 (no staining) to 4 (most staining).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal Conjunctival Lissamine Green Staining</measure>
    <time_frame>30 days</time_frame>
    <description>Nasal conjunctival lissamine green staining scored from 0 (no staining) to 4 (most staining).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Dry Eye</condition>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Treated followed by untreated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients wear the Hydra-PEG treated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the untreated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered prior to the control treatment (untreated scleral lenses).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated followed by treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients wear the untreated scleral lenses for 30 days. After testing and a post contact lens wear washout period, these patients will then wear the Hydra-PEG treated lenses for 30 days. In this arm, the intervention (scleral lenses treated with Tangible Hydra-PEG) is administered after the control treatment (untreated scleral lenses).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Scleral lenses treated with Tangible Hydra-PEG</intervention_name>
    <description>Scleral lenses treated with Tangible Hydra-PEG, a hydrophilic, PEG-based contact lens coating designed to improve lens wettability, deposit resistance, and tear film breakup time.</description>
    <arm_group_label>Treated followed by untreated</arm_group_label>
    <arm_group_label>Untreated followed by treated</arm_group_label>
    <other_name>Tangible Hydra-PEG is a hydrophilic PEG-based lens coating</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Untreated scleral lenses</intervention_name>
    <description>Scleral lenses without the Tangible Hydra-PEG treatment will serve as a control.</description>
    <arm_group_label>Treated followed by untreated</arm_group_label>
    <arm_group_label>Untreated followed by treated</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Reduced tear film break up time (TBUT), a sign of dry eye disease and contact lens
             discomfort

          -  Scleral lens wearer (at least 8 hours per day for at least 5 days per week and have
             had their habitual lenses no longer than 1 year). Scleral lenses wear will be defined
             as 15.00 mm to 19.00 mm inclusive.

        Exclusion Criteria:

          -  Disorders that affect sensitivity (herpetic disease, severe diabetes mellitus)

          -  Anatomic variations of the conjunctiva that can impair proper scleral lens fitting

          -  Pregnancy

          -  Best corrected Snellen visual acuity worse than 20/30 in either eye

          -  Ocular pathology other than dry eye (e.g. glaucoma, macular degeneration, keratoconus)
             which may significantly impact visual function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chandra Mickles, OD MS FAAO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nova Southeastern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Southeastern University</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois College of Optometry</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 10, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2018</study_first_posted>
  <results_first_submitted>December 20, 2019</results_first_submitted>
  <results_first_submitted_qc>January 7, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2020</results_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contact lens discomfort</keyword>
  <keyword>Scleral lens</keyword>
  <keyword>Tangible Hydra-PEG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT03417505/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Hydra-PEG Treated Lenses Followed by Untreated Lenses</title>
          <description>Hydra-PEG treated lenses were worn for 30 days, followed a one-week washout period and then 30 days wearing untreated lenses</description>
        </group>
        <group group_id="P2">
          <title>Untreated Lenses Followed by Hydra-PEG Treated Lenses</title>
          <description>Untreated lenses were worn for 30 days, followed a one-week washout period and then 30 days wearing Hydra-PEG treated lenses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Lens Type (30 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Lens Type (30 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants wore both the Hydra-PEG treated and untreated lenses in this crossover study, therefore the baseline characteristics are the same for both lens types.</population>
      <group_list>
        <group group_id="B1">
          <title>Participants</title>
          <description>As this was a crossover study, all participants work both the Hydra-PEG treated and untreated lenses. Therefore, the baseline characteristics were the same for both groups.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Surface Tear Breakup Time</title>
        <description>Tear breakup time of the ocular surface after wearing lenses</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Hydra-PEG Treated Lens Wearers</title>
            <description>Patients wearing the Hydra-PEG treated lenses</description>
          </group>
          <group group_id="O2">
            <title>Untreated Lens Wearers</title>
            <description>Patients wearing lenses without the Hydra-PEG treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Surface Tear Breakup Time</title>
          <description>Tear breakup time of the ocular surface after wearing lenses</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.81" spread="2.63"/>
                    <measurement group_id="O2" value="2.91" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Paired t-test comparison</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Corneal Fluorescein Staining</title>
        <description>Fluorescein staining followed by assessment using the Oxford grading scale (0-5, where 5 indicates the most staining and therefore the most damage to the ocular surface) of the ocular surface after wearing Hydra-PEG treated lenses compared to control lenses</description>
        <time_frame>30 days</time_frame>
        <population>All participants</population>
        <group_list>
          <group group_id="O1">
            <title>Hydra-PEG Treated Lens Wearers</title>
            <description>Patients wearing the Hydra-PEG treated lenses</description>
          </group>
          <group group_id="O2">
            <title>Untreated Lens Wearers</title>
            <description>Patients wearing lenses without the Hydra-PEG treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Fluorescein Staining</title>
          <description>Fluorescein staining followed by assessment using the Oxford grading scale (0-5, where 5 indicates the most staining and therefore the most damage to the ocular surface) of the ocular surface after wearing Hydra-PEG treated lenses compared to control lenses</description>
          <population>All participants</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="0.79"/>
                    <measurement group_id="O2" value="1.40" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Calculated p value was &lt;0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon signed rank comparisons, one-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Ocular Surface Disease Index (OSDI) Questionnaire</title>
        <description>Dry eye questionnaire to assess symptoms after wearing Hydra-PEG treated lenses compared to control lenses. Patients will be scored from 0 (no dry eye disease) to 100 (severe dry eye disease).</description>
        <time_frame>30 days</time_frame>
        <population>all participants</population>
        <group_list>
          <group group_id="O1">
            <title>Hydra-PEG Treated Lens Wearers</title>
            <description>Patients wearing the Hydra-PEG treated lenses</description>
          </group>
          <group group_id="O2">
            <title>Untreated Lens Wearers</title>
            <description>Patients wearing lenses without the Hydra-PEG treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Surface Disease Index (OSDI) Questionnaire</title>
          <description>Dry eye questionnaire to assess symptoms after wearing Hydra-PEG treated lenses compared to control lenses. Patients will be scored from 0 (no dry eye disease) to 100 (severe dry eye disease).</description>
          <population>all participants</population>
          <units>OSDI score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.24" spread="12.90"/>
                    <measurement group_id="O2" value="35.10" spread="17.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>paired 1-sided t-test</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)</title>
        <description>Validated dry eye questionnaire to assess symptoms after wearing Hydra-PEG treated lenses compared to control lenses. Scale is from 1 to 37, with higher scores indicating more dry eye symptoms.</description>
        <time_frame>30 days</time_frame>
        <population>all participants</population>
        <group_list>
          <group group_id="O1">
            <title>Hydra-PEG Treated Lens Wearers</title>
            <description>Patients wearing the Hydra-PEG treated lenses</description>
          </group>
          <group group_id="O2">
            <title>Untreated Lens Wearers</title>
            <description>Patients wearing lenses without the Hydra-PEG treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8)</title>
          <description>Validated dry eye questionnaire to assess symptoms after wearing Hydra-PEG treated lenses compared to control lenses. Scale is from 1 to 37, with higher scores indicating more dry eye symptoms.</description>
          <population>all participants</population>
          <units>CLDEQ-8 score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.89" spread="5.26"/>
                    <measurement group_id="O2" value="17.30" spread="6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>Wilcoxon signed rank comparison, one sided p value</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tear Breakup Time Over the Surface of the Scleral Lens</title>
        <description>Tear breakup time over the surface of the Hydra-PEG treated scleral lens compared to the control lens</description>
        <time_frame>30 days</time_frame>
        <population>all participants</population>
        <group_list>
          <group group_id="O1">
            <title>Hydra-PEG Treated Lens Wearers</title>
            <description>Patients wearing the Hydra-PEG treated lenses</description>
          </group>
          <group group_id="O2">
            <title>Untreated Lens Wearers</title>
            <description>Patients wearing lenses without the Hydra-PEG treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Breakup Time Over the Surface of the Scleral Lens</title>
          <description>Tear breakup time over the surface of the Hydra-PEG treated scleral lens compared to the control lens</description>
          <population>all participants</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.88" spread="5.17"/>
                    <measurement group_id="O2" value="4.75" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Calculated p value was &gt;0.05.</p_value_desc>
            <method>t-test, 1 sided</method>
            <method_desc>paired</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lid Wiper Epitheliopathy</title>
        <description>Fluorescein and lissamine staining to assess lid wiper epitheliopathy using a grading scale to see if there is a change in the height and width of the staining of the lid wiper area with Hydra-PEG treated lenses compared to untreated control lenses. The lid wiper area is the portion of the marginal conjunctival epithelium of the upper eyelid that wipes the ocular surface or lens during blinking. Epitheliopathy is scored on a scale from 0 (best patient outcome) to 3 (worst patient outcome, more staining) on the basis of the horizontal and vertical extent of lid margin staining.</description>
        <time_frame>30 days</time_frame>
        <population>all participants analyzed with each lens type</population>
        <group_list>
          <group group_id="O1">
            <title>Hydra-PEG Treated Lens Wearers</title>
            <description>Patients wearing the Hydra-PEG treated lenses</description>
          </group>
          <group group_id="O2">
            <title>Untreated Lens Wearers</title>
            <description>Patients wearing lenses without the Hydra-PEG treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Lid Wiper Epitheliopathy</title>
          <description>Fluorescein and lissamine staining to assess lid wiper epitheliopathy using a grading scale to see if there is a change in the height and width of the staining of the lid wiper area with Hydra-PEG treated lenses compared to untreated control lenses. The lid wiper area is the portion of the marginal conjunctival epithelium of the upper eyelid that wipes the ocular surface or lens during blinking. Epitheliopathy is scored on a scale from 0 (best patient outcome) to 3 (worst patient outcome, more staining) on the basis of the horizontal and vertical extent of lid margin staining.</description>
          <population>all participants analyzed with each lens type</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.76"/>
                    <measurement group_id="O2" value="1.41" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Calculated p value was &lt;0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>paired, 1-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Contact Lens-related Papillary Conjunctivitis</title>
        <description>Visual inspection for contact lens-related papillary conjunctivitis with scoring by the Efron grading scale for papillary conjunctivitis [0 (normal) to 4 (severe)] to assess changes after wear of Hydra-PEG treated lenses compared to control lenses.</description>
        <time_frame>30 days</time_frame>
        <population>all participants were analyzed in each lens type</population>
        <group_list>
          <group group_id="O1">
            <title>Hydra-PEG Treated Lens Wearers</title>
            <description>Patients wearing the Hydra-PEG treated lenses</description>
          </group>
          <group group_id="O2">
            <title>Untreated Lens Wearers</title>
            <description>Patients wearing lenses without the Hydra-PEG treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Contact Lens-related Papillary Conjunctivitis</title>
          <description>Visual inspection for contact lens-related papillary conjunctivitis with scoring by the Efron grading scale for papillary conjunctivitis [0 (normal) to 4 (severe)] to assess changes after wear of Hydra-PEG treated lenses compared to control lenses.</description>
          <population>all participants were analyzed in each lens type</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.66"/>
                    <measurement group_id="O2" value="1.45" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>paired, 1-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Temporal Conjunctival Lissamine Green Staining</title>
        <description>Temporal conjunctival lissamine green staining scored 0 (no staining) to 4 (most staining).</description>
        <time_frame>30 days</time_frame>
        <population>all participants analyzed in both lens types</population>
        <group_list>
          <group group_id="O1">
            <title>Hydra-PEG Treated Lens Wearers</title>
            <description>Patients wearing the Hydra-PEG treated lenses</description>
          </group>
          <group group_id="O2">
            <title>Untreated Lens Wearers</title>
            <description>Patients wearing lenses without the Hydra-PEG treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Temporal Conjunctival Lissamine Green Staining</title>
          <description>Temporal conjunctival lissamine green staining scored 0 (no staining) to 4 (most staining).</description>
          <population>all participants analyzed in both lens types</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="0.79"/>
                    <measurement group_id="O2" value="1.23" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Calculated p value was &lt;0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>paired, 1-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nasal Conjunctival Lissamine Green Staining</title>
        <description>Nasal conjunctival lissamine green staining scored from 0 (no staining) to 4 (most staining).</description>
        <time_frame>30 days</time_frame>
        <population>all participants were analyzed in both lens types</population>
        <group_list>
          <group group_id="O1">
            <title>Hydra-PEG Treated Lens Wearers</title>
            <description>Patients wearing the Hydra-PEG treated lenses</description>
          </group>
          <group group_id="O2">
            <title>Untreated Lens Wearers</title>
            <description>Patients wearing lenses without the Hydra-PEG treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Nasal Conjunctival Lissamine Green Staining</title>
          <description>Nasal conjunctival lissamine green staining scored from 0 (no staining) to 4 (most staining).</description>
          <population>all participants were analyzed in both lens types</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.71"/>
                    <measurement group_id="O2" value="1.03" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <p_value_desc>Calculated p value was &gt;0.05.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
            <method_desc>paired, 1-sided</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected throughout the period of the study (a period of 79 days for each participant).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Hydra-PEG Treated Lenses Followed by Untreated Lenses</title>
          <description>Participants wore Hydra-PEG lenses for 30 days, followed by a 7 day washout period and then 30 days wearing untreated lenses.</description>
        </group>
        <group group_id="E2">
          <title>Untreated Lenses Followed by Hydra-PEG Treated Lenses</title>
          <description>Participants wore untreated lenses for 30 days, followed by a 7 day washout period and then 30 days wearing Hydra-PEG treated lenses.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI has the right to publish results from the study. The Sponsor has 30 days to review communications prior to publication with respect to the disclosure of confidential information (study results would not qualify as confidential information).</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kelly Mabry</name_or_title>
      <organization>Tangible Science</organization>
      <phone>650-241-1045 ext 108</phone>
      <email>kelly@tangiblescience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

